Company Research Report: Alentis Therapeutics AG

Company Overview

Name: Alentis Therapeutics AG

Mission: Alentis is dedicated to treating cancer and reversing fibrosis through the development of anti-Claudin-1 therapies.

Founded: 2019

Founder: Professor Thomas Baumert

Key People:

Roberto Iacone, Chief Executive Officer

Luigi Manenti, Chief Medical Officer

Jon Freve, Chief Financial Officer

Rizwan Velji, Chief Business Officer

Markus Meyer, Chief Operating Officer

Alberto Toso, Chief Scientific Officer

Valentina Aureggi, SVP BD & Strategic Partnerships

Geoffrey Teixeira, SVP Head of Fibrosis

Thomas Baumert, Founder

Headquarters: Hegenheimermattweg 167A, 4123 Allschwil, Switzerland

Number of Employees: Over 50 employees

Revenue: No information is available

Known For: Alentis is recognized as the leading biotech company developing therapies targeting Claudin-1, focusing on solid tumors and fibrosis.

Products

Anti-Claudin-1 Therapeutics

1. ALE.C04

Description: A first-in-class monoclonal antibody developed for Claudin-1 positive cancer indications.

Key Features:

Designed to selectively target CLDN1+ tumor cells.

Opens the collagen barrier for immune system or immunotherapy access.

Granted FDA Fast Track designation for treatment of head and neck squamous cell carcinoma.

2. ALE.P02 & ALE.P03

Description: Novel antibody-drug conjugates (ADCs) designed for CLDN1+ cancer indications.

Key Features:

ALE.P02 uses a tubulin inhibitor.

ALE.P03 uses a topoisomerase I inhibitor.

ADCs possess a unique mechanism for targeted tumor destruction with minimized healthy tissue toxicity.

3. Lixudebart (ALE.F02)

Description: A first-in-class antibody developed for fibrosis, targeting liver, kidney, and lung.

Key Features:

Blocks fibrotic signaling.

Breaks down the collagen barrier.

Clinical trials target ANCA-associated vasculitis and idiopathic pulmonary fibrosis.

Recent Developments

Innovations and Collaborations

FDA Fast Track Designations: ALE.C04 for head and neck squamous cell carcinoma, ALE.P02 for squamous cancers irrespective of the origin.

Series D Financing: Raised $181.4 million with lead contributions from OrbiMed, Novo Holdings, and Jeito Capital, fueling pipeline advancements.

Phase 1/2 Clinical Trials: Initiation and planning for ALE.C04 and ALE.P02 in late-stage cancer conditions.

New Appointments

Jon Freve CFO: Appointed as Chief Financial Officer.

Alberto Toso: Appointed as Chief Scientific Officer.

Partnerships and Events

Collaborated with leading scientific communities like ERA and ATS for fibrosis research discussions.

Sponsored the 3rd International Summit on Lung Cancer.

Financial Growth

Series D funding led by top-tier investors to support the clinical development of ADCs and further compound development.

Previous Series C and B rounds raised $105 million and $67 million, supporting pivotal phases of the therapeutic pipeline.

Conclusion

Alentis Therapeutics AG is at the forefront of biotechnology focusing on novel anti-Claudin-1 antibody therapies to combat fibrotic diseases and cancers marked by specific unmet needs. The company's strong leadership, innovative pipeline, recent significant fundraising, and strategic FDA designations position it for pioneering advancements in therapeutic solutions.

Additional Resources

For further details, visit the official website: [Alentis Therapeutics AG](http://www.alentis.ch)

Contact: Nathalie Graf, Office Manager | E-mail: info@alentis.ch